Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials

Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials

BackgroundIn patients with type 2 diabetes (T2D) and a history of heart failure (HF), sodium–glucose cotransporter-2 inhibitors (SGLT2is) have demonstrated cardiovascular (CV) benefits. However, the comparative efficacy of individual SGLT2is remains uncertain. This network meta-analysis (NMA) compar...

Full description

Bibliographic Details
Main Authors: Tanawan Kongmalai, Phorntida Hadnorntun, Pattara Leelahavarong, Pinkawas Kongmalai, Varalak Srinonprasert, Srisakul Chirakarnjanakorn, Usa Chaikledkaew, Gareth McKay, John Attia, Ammarin Thakkinstian
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Endocrinology
Subjects:
sodium-glucose cotransporter 2 inhibitor (SGLT2 inhibitor)
congestive heart failure
cardiovascular disease
diabetes mellitus
systematic review
network meta-analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2023.1216160/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2023.1216160/full

Similar Items